Glenmarks novel monoclonal antibody GBR 830 to enter phase II clinical studies
GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Glenmark Pharmaceuticals GBR 830, a novel monoclonal antibody has completed clinical phase I dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation []03-09-2015